Results 211 to 220 of about 77,046 (263)

Novel treatments in B cell non-Hodgkin’s lymphomas

BMJ, 2022
ABSTRACT The improved understanding of lymphoma biology and recent advances in the field of cancer immunology have paved the way for the development of many effective small molecule inhibitors and immunotherapies in B cell non-Hodgkin’s lymphomas.
Yazeed, Sawalha, Kami, Maddocks
openaire   +2 more sources

Radioimmunotherapy for B-cell non-Hodgkin lymphoma

Best Practice & Research Clinical Haematology, 2006
Radioimmunotherapy (RIT) combines the targeting advantage of a monoclonal antibody with the radiosensitivity of non-Hodgkin lymphoma (NHL) cells. There are now two radioimmunoconjugates (RICs) - ibritumomab tiuxetan (Zevalin) and tositumomab (Bexxar) - that are approved by the FDA in the US for relapsed low-grade or follicular B-cell NHL.
Grzegorz S, Nowakowski, Thomas E, Witzig
openaire   +4 more sources

Radioimmunotherapy of B-cell non-Hodgkin's lymphoma

European Journal of Nuclear Medicine, 2001
In the past decade, several new antibody-based therapies - using either radiolabelled or unlabelled monoclonal antibodies - have become available for the treatment of patients with refractory or recurrent non-Hodgkin's lymphoma (NHL). Unlabelled monoclonal antibodies (mAbs) kill lymphoma cells by activating host immune effector mechanisms, or by ...
Postema, E.J., Boerman, O.C., Oyen, W.J.G., Raemaekers, J.M.M., Corstens, F.H.M.   +4 more
openaire   +3 more sources

Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update

Seminars in Nuclear Medicine, 2023
Systemic radioimmunotherapy (RIT) is arguably the most effective and least toxic anticancer treatment for non-Hodgkin lymphoma (NHL). In treatment-naïve patients with indolent NHL, the efficacy of a single injection of RIT compares with that of multiple cycles of combination chemotherapy.
Francesco Cicone, Giulia Santo, Caroline Bodet-Milin, Giuseppe Lucio Cascini, Françoise Kraeber-Bodéré, Caroline Stokke, Arne Kolstad   +6 more
openaire   +3 more sources

Laryngeal Manifestation of B-Cell Non-Hodgkin Lymphoma

Acta Otorrinolaringologica (English Edition), 2012
Laryngeal lymphomas are rare, involving less than 1% of all laryngeal tumours. Extranodal non-Hodgkin lymphomas generally appear in places where lymphoid tissue exists, such as the small bowel or parotid; they are very unusual in organs with little or no presence of lymphoid tissue, such as the larynx.
Jhonder Xavier, Salazar Guilarte, Manuela, Sancho Mestre, Juan Ramón, Gras Albert   +2 more
openaire   +2 more sources

Monoclonal gammopathies in B-cell non-Hodgkin’s lymphomas

Leukemia Research, 2003
The association of monoclonal gammopathy (MG) with B-cell non-Hodgkin's lymphomas (NHL) is a well known phenomenon. The aim of the present work was to study the incidence, type of monoclonal component and prognostic significance of MG in a population of 255 cases with B-cell NHL.
T, Economopoulos, S, Papageorgiou, V, Pappa, E, Papageorgiou, S, Valsami, D, Kalantzis, N, Xiros, J, Dervenoulas, S, Raptis   +8 more
openaire   +2 more sources

B-cell Non-Hodgkin Lymphomas with Plasmacytic Differentiation

Surgical Pathology Clinics, 2016
B-cell non-Hodgkin lymphomas with plasmacytic differentiation are a diverse group of entities with extremely variable morphologic features. Diagnostic challenges can arise in differentiating lymphoplasmacytic lymphoma from marginal zone lymphoma and other low-grade B-cell lymphomas.
Charles M, Harmon, Lauren B, Smith
openaire   +2 more sources

Use of bortezomib in B-cell non-Hodgkin’s lymphoma

Expert Review of Anticancer Therapy, 2006
The ubiquitin-proteasome pathway plays a critical role in the regulated degradation of proteins involved in cell cycle control and tumor growth. Bortezomib (Velcade, formerly known as PS-341) is a potent proteasome inhibitor. In preclinical studies, bortezomib has demonstrated activity against a variety of B-cell malignancies by inducing apoptosis and ...
Michael, Wang, Yuhong, Zhou, Liang, Zhang, C Ann, Nguyen, Jorge, Romaguera   +4 more
openaire   +2 more sources

HCV and HGV in B-cell non-Hodgkin's lymphoma

Journal of Hepatology, 1998
A causative role of hepatitis C virus infection (HCV) has been discussed in the pathogenesis of mixed cryoglobulinaemia and in B-cell non-Hodgkin's lymphoma. No data are available concerning the newly discovered hepatitis G virus (HGV) and extrahepatic manifestations such as haematological malignancies. But, HCV and HGV most probably belong to the same
V, Ellenrieder, H, Weidenbach, N, Frickhofen, D, Michel, O, Prümmer, S, Klatt, O, Bernas, T, Mertens, G, Adler, K, Beckh   +9 more
openaire   +2 more sources